4.7 Article

Endothelial cells induce cancer stem cell features in differentiated glioblastoma cells via bFGF

期刊

MOLECULAR CANCER
卷 14, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/s12943-015-0420-3

关键词

Glioblastoma multiforme; Cancer stem cells; Tumor microenvironment; Dedifferentiation

资金

  1. VICI grant from the Netherlands Organization for Scientific Research
  2. Dutch Cancer Society grant [2012-5425]
  3. Academic Medical Center (AMC) Graduate School PhD Scholarship

向作者/读者索取更多资源

Background: Glioblastoma multiforme (GBM) is a rapidly growing malignant brain tumor, which has been reported to be organized in a hierarchical fashion with cancer stem cells (CSCs) at the apex. Recent studies demonstrate that this hierarchy does not follow a one-way route but can be reverted with more differentiated cells giving rise to cells possessing CSC features. We investigated the role of tumor microvascular endothelial cells (tMVECs) in reverting differentiated glioblastoma cells to CSC-like cells. Methods: We made use of primary GBM lines and tMVECs. To ensure differentiation, CSC-enriched cultures were forced into differentiation using several stimuli and cultures consisting solely of differentiated cells were obtained by sorting on the oligodendrocyte marker O4. Reversion to the CSC state was assessed phenotypically by CSC marker expression and functionally by evaluating clonogenic and multilineage differentiation potential. Results: Conditioned medium of tMVECs was able to replenish the CSC pool by phenotypically and functionally reverting differentiated GBM cells to the CSC state. Basic fibroblast growth factor (bFGF), secreted by tMVECs, recapitulated the effects of the conditioned medium in inducing re-expression of CSC markers and increasing neurosphere formation ability of differentiated GBM cells. Conclusions: Our findings demonstrate that the CSC-based hierarchy displays a high level of plasticity showing that differentiated GBM cells can acquire CSC features when placed in the right environment. These results point to the need to intersect the elaborate network of tMVECs and GBM CSCs for efficient elimination of GBM CSCs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Rapid stromal remodeling by short-term VEGFR2 inhibition increases chemotherapy delivery in esophagogastric adenocarcinoma

Anne Steins, Remy Klaassen, Igor Jacobs, Matthias C. Schabel, Monique G. J. T. B. van Lier, Eva A. Ebbing, Stefanie J. Hectors, Sander W. Tas, Chrissta X. Maracle, Cornelis J. A. Punt, Maria Siebes, Jacques J. G. H. M. Bergman, Jan Paul Medema, Johanna W. Wilmink, Ron A. A. Mathot, Gustav J. Strijkers, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven

MOLECULAR ONCOLOGY (2020)

Review Biochemistry & Molecular Biology

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy

Prashanthi Ramesh, Jan Paul Medema

APOPTOSIS (2020)

Article Biochemistry & Molecular Biology

High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1

Anne Steins, Madelaine G. van Mackelenbergh, Amber P. van der Zalm, Remy Klaassen, Bryan Serrels, Sandrine G. Goris, Hemant M. Kocher, Cynthia Waasdorp, Joan H. de Jong, Cansu Tekin, Marc G. Besselink, Olivier R. Busch, Marc J. van de Vijver, Joanne Verheij, Frederike Dijk, Geertjan van Tienhoven, Johanna W. Wilmink, Jan Paul Medema, Hanneke W. M. van Laarhoven, Maarten F. Bijlsma

EMBO REPORTS (2020)

Article Chemistry, Multidisciplinary

Nanostructured toxins for the selective destruction of drug-resistant human CXCR4+ colorectal cancer stem cells

Naroa Serna, Patricia Alamo, Prashanthi Ramesh, Daria Vinokurova, Laura Sanchez-Garcia, Ugutz Unzueta, Alberto Gallardo, Maria Virtudes Cespedes, Esther Vazquez, Antonio Villaverde, Ramon Mangues, Jan Paul Medema

JOURNAL OF CONTROLLED RELEASE (2020)

Article Biochemistry & Molecular Biology

RNF43 truncations trap CK1 to drive niche-independent self-renewal in cancer

Maureen Spit, Nicola Fenderico, Ingrid Jordens, Tomasz Radaszkiewicz, Rik G. H. Lindeboom, Jeroen M. Bugter, Alba Cristobal, Lars Ootes, Max van Osch, Eline Janssen, Kim E. Boonekamp, Katerina Hanakova, David Potesil, Zbynek Zdrahal, Sylvia F. Boj, Jan Paul Medema, Vitezslav Bryja, Bon-Kyoung Koo, Michiel Vermeulen, Madelon M. Maurice

EMBO JOURNAL (2020)

Review Oncology

Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges

Joyce Y. Buikhuisen, Arezo Torang, Jan Paul Medema

ONCOGENESIS (2020)

Article Oncology

Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study

I. van den Berg, S. van de Weerd, J. M. L. Roodhart, G. R. Vink, R. R. J. Coebergh van den Braak, C. R. Jimenez, S. G. Elias, D. van Vliet, M. Koelink, E. Hong, W. M. U. van Grevenstein, M. G. H. van Oijen, R. G. H. Beets-Tan, J. H. J. M. van Krieken, J. N. M. IJzermans, J. P. Medema, M. Koopman

BMC CANCER (2020)

Article Oncology

Interconnectivity between molecular subtypes and tumor stage in colorectal cancer

R. R. J. Coebergh van den Braak, S. ten Hoorn, A. M. Sieuwerts, J. B. Tuynman, M. Smid, S. M. Wilting, J. W. M. Martens, C. J. A. Punt, J. A. Foekens, J. P. Medema, J. N. M. IJzermans, L. Vermeulen

BMC CANCER (2020)

Article Multidisciplinary Sciences

Driver mutations of the adenoma-carcinoma sequence govern the intestinal epithelial global translational capacity

Wouter Laurentius Smit, Claudia Nanette Spaan, Ruben Johannes de Boer, Prashanthi Ramesh, Tania Martins Garcia, Bartolomeus Joannes Meijer, Jacqueline Ludovicus Maria Vermeulen, Marco Lezzerini, Alyson Winfried MacInnes, Jan Koster, Jan Paul Medema, Gijs Robert van den Brink, Vanesa Muncan, Jarom Heijmans

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Gastroenterology & Hepatology

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells

Laura Rosa Mangiapane, Annalisa Nicotra, Alice Turdo, Miriam Gaggianesi, Paola Bianca, Simone Di Franco, Davide Stefano Sardina, Veronica Veschi, Michele Signore, Sven Beyes, Luca Fagnocchi, Micol Eleonora Fiori, Maria Rita Bongiorno, Melania Lo Iacono, Irene Pillitteri, Gloria Ganduscio, Gaspare Gulotta, Jan Paul Medema, Alessio Zippo, Matilde Todaro, Ruggero De Maria, Giorgio Stassi

Summary: In colorectal cancer stem cells, high HER2 expression levels are associated with activation of the PI3K/AKT pathway. The targeting of HER2 in combination with PI3K and MEK inhibitors induces CR-CSC death and regression of tumor xenografts, including those with specific mutations. Triple targeting of PI3K, HER2, and MEK is necessary to overcome resistance to anti-EGFR therapies.
Article Multidisciplinary Sciences

A RAC-GEF network critical for early intestinal tumourigenesis

K. A. Pickering, K. Gilroy, J. W. Cassidy, S. K. Fey, A. K. Najumudeen, L. B. Zeiger, D. F. Vincent, D. M. Gay, J. Johansson, R. P. Fordham, B. Miller, W. Clark, A. Hedley, E. B. Unal, C. Kiel, E. McGhee, L. M. Machesky, C. Nixon, A. E. Johnsson, M. Bain, D. Strathdee, S. R. van Hoof, J. P. Medema, K. Anderson, S. M. Brachmann, V. M. Stucke, A. Malliri, M. Drysdale, M. Turner, L. Serrano, K. Myant, A. D. Campbell, O. J. Sansom

Summary: Indirect targeting of RAC1 via RAC-GEFs can effectively suppress hyperproliferation and tumorigenesis in the murine intestine without affecting normal intestinal homeostasis. Combined targeting of three RAC-GEFs can effectively inhibit RAC1 activity and delay intestinal tumorigenesis.

NATURE COMMUNICATIONS (2021)

Article Oncology

AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition

Joyce Y. Buikhuisen, Patricia M. Gomez Barila, Arezo Torang, Danielle Dekker, Joan H. de Jong, Kate Cameron, Sara Vitale, Giorgio Stassi, Sander R. van Hooff, Mauro A. A. Castro, Louis Vermeulen, Jan Paul Medema

Summary: The study identified that the protein AKT3 is highly expressed in CMS4 colorectal cancer subtype, promoting cancer cell growth by inhibiting the cell cycle regulator p27(KIP1). Inhibitors targeting AKT3 significantly reduced the growth of CMS4 categorized cancer cell lines. High AKT3 expression may serve as a marker for poor prognosis in colorectal cancer patients and could potentially guide the selection of patients who could benefit from AKT3-targeted therapy.

CANCERS (2021)

Article Oncology

Daily practice in guideline adherence to adjuvant chemotherapy in stage III colon cancer and predictors of outcome

I van den Berg, S. van de Weerd, D. van Klaveren, R. R. J. Coebergh van den Braak, J. H. J. M. van Krieken, M. Koopman, J. M. L. Roodhart, J. P. Medema, J. N. M. IJzermans

Summary: This study revealed significant variation in guideline adherence to adjuvant chemotherapy among stage III colon cancer patients, with poor documentation on reasons for non-adherence. Patients who received adjuvant chemotherapy had longer recurrence free survival (RFS), and high T- and N-stage were associated with poorer RFS. Risk groups were identified with distinct prognosis and treatment effect, emphasizing the importance of adherence to guidelines for improved patient outcomes.
Article Biochemistry & Molecular Biology

BH3 Mimetic Sensitivity of Colorectal Cancer Cell Lines in Correlation with Molecular Features Identifies Predictors of Response

Le Zhang, Prashanthi Ramesh, Maxime Steinmetz, Jan Paul Medema

Summary: The study found that colorectal cancer cells have different responses to BH3 mimetics, which can be predicted by their consensus molecular subtype and KRAS/BRAF mutations. Most colorectal cancer cell lines are sensitive to combined MCL-1 and BCL-XL targeting in the nanomolar range.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Article Economics

Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)

Gabrielle Jongeneel, Marjolein J. E. Greuter, Felice N. van Erning, Miriam Koopman, Jan P. Medema, Raju Kandimalla, Ajay Goel, Luis Bujanda, Gerrit A. Meijer, Remond J. A. Fijneman, Martijn G. H. van Oijen, Jan Ijzermans, Cornelis J. A. Punt, Geraldine R. Vink, Veerle M. H. Coupe

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)

暂无数据